(Q38106847)

29 August 2017

title

The immunogenicity of polyethylene glycol: facts and fiction (English)

1 reference

29 August 2017

Huub Schellekens

1

1 reference

29 August 2017

Wim E Hennink

series ordinal

2

1 reference

29 August 2017

Vera Brinks

series ordinal

3

1 reference

29 August 2017

publication date

15 May 2013

1 reference

29 August 2017

published in

Pharmaceutical Research

1 reference

29 August 2017

volume

30

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

1729-1734

1 reference

Product development issues for PEGylated proteins

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

21 January 2018

Emerging PEGylated drugs

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

State of the art in PEGylation: the great versatility achieved after forty years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Role of the methoxy group in immune responses to mPEG-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

How to predict and prevent the immunogenicity of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1067-7

Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes

21 January 2018

1 reference

12 December 2020

Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes

1 reference

12 December 2020

PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner

1 reference

12 December 2020

Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes

1 reference

12 December 2020

Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.

1 reference

12 December 2020

Repeated injections of PEG-PE liposomes generate anti-PEG antibodies.

1 reference

12 December 2020

Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies

1 reference

12 December 2020

Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors

1 reference

12 December 2020

Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance

1 reference

12 December 2020

A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers

1 reference

12 December 2020

Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins

1 reference

12 December 2020

Accelerated clearance of PEGylated liposomes in rats after repeated injections

1 reference

12 December 2020

Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion

1 reference

12 December 2020

Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response

1 reference

12 December 2020

Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA

1 reference

12 December 2020

10.1007/S11095-013-1067-7

Identifiers

DOI

1 reference

29 August 2017

1 reference